Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk A/S has a research and licensing agreement with DUKE National University Singapore Medical School to develop stem cell-based treatments for chronic heart failure and age-related macular degeneration. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVO
CUSIPN/A
Phone45-4444-8888
Debt
Debt-to-Equity RatioN/A
Current Ratio1.13
Quick Ratio0.77
Price-To-Earnings
Trailing P/E Ratio21.32
Forward P/E Ratio19.79
P/E Growth2.66
Sales & Book Value
Annual Sales$16.96 billion
Price / Sales7.19
Cash Flow$2.5672 per share
Price / Cash19.43
Book Value$3.10 per share
Price / Book16.09
Profitability
EPS (Most Recent Fiscal Year)$2.34
Net Income$5.79 billion
Net Margins35.21%
Return on Equity82.77%
Return on Assets40.01%
Miscellaneous
Employees42,076
Outstanding Shares2,443,530,000
Market Cap$121,883.18
Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions
What is Novo Nordisk A/S's stock symbol?
Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."
How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?
Novo Nordisk A/S announced a special dividend on Monday, February 5th. Stockholders of record on Monday, March 26th will be given a dividend of $0.8117 per share on Tuesday, April 3rd. This represents a dividend yield of 0.96%. The ex-dividend date is Friday, March 23rd. View Novo Nordisk A/S's Dividend History.
How will Novo Nordisk A/S's stock buyback program work?
Novo Nordisk A/S declared that its board has approved a share buyback program on Friday, February 2nd 2018, which permits the company to buyback shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Shares buyback programs are often an indication that the company's board of directors believes its shares are undervalued.
How were Novo Nordisk A/S's earnings last quarter?
Novo Nordisk A/S (NYSE:NVO) issued its earnings results on Wednesday, May, 2nd. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.69 by $0.04. The firm earned $4.44 billion during the quarter, compared to analyst estimates of $4.49 billion. Novo Nordisk A/S had a return on equity of 82.77% and a net margin of 35.21%. View Novo Nordisk A/S's Earnings History.
When is Novo Nordisk A/S's next earnings date?
What is the consensus analysts' recommendation for Novo Nordisk A/S?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Novo Nordisk A/S's key competitors?
Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).
Who are Novo Nordisk A/S's key executives?
Novo Nordisk A/S's management team includes the folowing people:
- Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 52)
- Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 58)
- Mr. Jesper Brandgaard, Exec. VP and Head of Biopharm & Legal Affairs (Age 55)
- Ms. Liselotte Hyveled, Former Project VP for Faster-Acting Insulin Aspart & Prandial Bioedge Projects - Insulin & Director (Age 52)
- Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 46)
Has Novo Nordisk A/S been receiving favorable news coverage?
Headlines about NVO stock have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novo Nordisk A/S earned a media sentiment score of 0.04 on Accern's scale. They also gave headlines about the company an impact score of 48.33 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Novo Nordisk A/S's major shareholders?
Novo Nordisk A/S's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.56%), Cim LLC (0.01%), Ledyard National Bank (0.01%), JLB & Associates Inc. (0.01%) and Norman Fields Gottscho Capital Management LLC (0.00%). View Institutional Ownership Trends for Novo Nordisk A/S.
Which major investors are selling Novo Nordisk A/S stock?
Which major investors are buying Novo Nordisk A/S stock?
How do I buy shares of Novo Nordisk A/S?
Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novo Nordisk A/S's stock price today?
One share of NVO stock can currently be purchased for approximately $49.88.
How big of a company is Novo Nordisk A/S?
Novo Nordisk A/S has a market capitalization of $121.88 billion and generates $16.96 billion in revenue each year. The company earns $5.79 billion in net income (profit) each year or $2.34 on an earnings per share basis. Novo Nordisk A/S employs 42,076 workers across the globe.
How can I contact Novo Nordisk A/S?
Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]
MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
